Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome
Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
See All Discussions